ResMed Inc.

As of June 30, 2026, ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh carries a market capitalization of 41.83B, placing it among publicly traded companies globally. Its enterprise value stands at 40.90B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh's next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh has 1.45B shares outstanding.

As of June 30, 2026, ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh trades at a trailing price-to-earnings ratio of 19.17. The price-to-sales ratio is 5.17, and the price-to-book ratio stands at 4.40.

As of June 30, 2026, ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh trades at an EV/EBITDA multiple of 13.28 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 5.01 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 15.00 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh trades at an EV/FCF ratio of 17.38, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 40.90B versus a market cap of 41.83B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh maintains a current ratio of 3.10, meaning it holds 3.1x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh posted a return on equity (ROE) of 24.27, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 20.67 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 17.77, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 21.41, useful for judging operating efficiency across full business cycles. The company generates approximately 756,935.38 in revenue per employee across its workforce of 10,792.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.35 indicates how many times ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh recorded 572.40M in income tax expense. That works out to an effective tax rate of 20.64, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 2.77B, leaving 2.20B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh's stock has declined approximately 15.45% over the past 52 weeks. The 50-day moving average sits at 32.19, while the 200-day moving average is 31.86.

Over the twelve months ended June 30, 2026, ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh generated 8.17B in revenue and converted that into 2.20B in net income, yielding earnings per share of 1.50. EBITDA reached 3.08B, while operating income came in at 2.76B.

As of June 30, 2026, ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh holds 2.12B in cash and equivalents against 1.19B in total debt, resulting in a net debt position of -1.17B. Total book value stands at 9.52B, with working capital of 4.23B providing operational flexibility.

ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh produced 2.61B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -256.01M in capital expenditures, free cash flow totaled 2.35B - equivalent to 1.61 per share.

Over the twelve months ended June 30, 2026, ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh posted a gross margin of 61.06, reflecting its pricing power and cost economics. The operating margin of 33.76 and net profit margin of 26.94 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh paid dividends of 0.35 per share. The dividend payout ratio of 22.95 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 5.56, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 3.48, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh shareholders.

ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh's most recent stock split took place on August 12, 2010 with a 1:2 split ratio.

As of June 30, 2026, ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh has an Altman Z-Score of 11.87, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.